BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Agoglia L, Balbi E, Halpern M, Roma J, Carius L, Martinho J, Moreira L. Tuberculosis in Liver Transplant Recipients: Prophylaxis in an Endemic Area. Transplantation Proceedings 2011;43:199-202. [DOI: 10.1016/j.transproceed.2010.12.033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Lauar ID, Faria LC, Romanelli RMC, Clemente WT. Latent tuberculosis: Risk factors, screening and treatment in liver transplantation recipients from an endemic area. World J Transplant 2021; 11(12): 512-522 [DOI: 10.5500/wjt.v11.i12.512] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kim SH, Oh S, Nham E, Ko JH, Huh K, Cho SY, Kang CI, Chung DR, Choi GS, Kim JM, Joh JW, Peck KR. Risk Groups of Developing Active Tuberculosis in Liver Transplant Recipients in a Tuberculosis Endemic Area: Risk Stratification by Chest Image and Interferon Gamma Release Assay. Int J Infect Dis 2021;113:359-66. [PMID: 34718154 DOI: 10.1016/j.ijid.2021.10.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Korayem GB, Alissa DA, AlSuhaibani NI, AlSwailem GS, AlShammari MA, Yaqoob I, Aljasser DS, Almaghrabi RS. Empiric vs screening-based use of isoniazid for tuberculosis prophylaxis: Safety and effectiveness in lung transplant recipients in Saudi Arabia. Transpl Infect Dis 2021;23:e13473. [PMID: 32978858 DOI: 10.1111/tid.13473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Abad CL, Razonable RR. Prevention and treatment of tuberculosis in solid organ transplant recipients. Expert Rev Anti Infect Ther 2020;18:63-73. [PMID: 31826668 DOI: 10.1080/14787210.2020.1704255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Abad CLR, Deziel PJ, Razonable RR. Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review. Transpl Infect Dis 2019;21:e13178. [PMID: 31541575 DOI: 10.1111/tid.13178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ayuk AC, Gray D, Vanker A, Zampoli M. Tuberculosis in children presenting with chylothorax - Report of two cases and review of the literature. Respir Med Case Rep 2019;27:100848. [PMID: 31049284 DOI: 10.1016/j.rmcr.2019.100848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Philley JV, Griffith DE. Antimycobacterial Consideration in Transplantation Including Drug Non-susceptibility and Resistance: Tuberculosis and Nontuberculous Mycobacterial Disease. Principles and Practice of Transplant Infectious Diseases 2019. [DOI: 10.1007/978-1-4939-9034-4_56] [Reference Citation Analysis]
8 Moon HH, Park SY, Kim JM, Park JB, Kwon CHD, Peck KR, Kim SJ, Lee SK, Joh JW. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area. Ann Transplant. 2017;22:338-345. [PMID: 28579606 DOI: 10.12659/aot.902989] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
9 Muñoz L, Santin M. Prevention and Management of Tuberculosis in Transplant Recipients: From Guidelines to Clinical Practice. Transplantation 2016;100:1840-52. [DOI: 10.1097/tp.0000000000001224] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
10 Nagral S, Nanavati A, Nagral A. Liver Transplantation in India: At the Crossroads. J Clin Exp Hepatol 2015;5:329-40. [PMID: 26900275 DOI: 10.1016/j.jceh.2015.11.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
11 Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM; ESCMID Study Group of Infection in Compromised Hosts. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:89-101. [PMID: 24707957 DOI: 10.1111/1469-0691.12641] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 9.0] [Reference Citation Analysis]
12 Stucchi R, Boin I, Angerami R, Zanaga L, Ataide E, Udo E. Is Isoniazid Safe for Liver Transplant Candidates With Latent Tuberculosis? Transplantation Proceedings 2012;44:2406-10. [DOI: 10.1016/j.transproceed.2012.07.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
13 Fraisse P. Diagnostic des infections tuberculeuses latentes (sujets sains, sujets immunodéprimés ou amenés à l’être). Revue des Maladies Respiratoires 2012;29:277-318. [DOI: 10.1016/j.rmr.2011.05.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
14 Rajagopala S, Olithselvan A, Varghese J, Shanmugam N, Rela M. Latent Mycobacterium tuberculosis Infection in Liver Transplant Recipients-Controversies in Current Diagnosis and Management. J Clin Exp Hepatol 2011;1:34-7. [PMID: 25755308 DOI: 10.1016/S0973-6883(11)60120-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]